NPC in Chain Drug Review: Let's Address Health System Improvements in 2019
(1/9, National Pharmaceutical Council: E.V.I.dently Today) comments “In his latest column for Chain Drug Review, National Pharmaceutical Council President and Chief Executive Officer Dan Leonard looks deeper into 2019 and explores how we can take a more holistic approach toward addressing health care spending and getting it under control. Read the column to learn how value-based contracting, improved understanding of costs, reducing low-value care, and regulatory and legislative changes can help drive the health care system in the United States toward greater value for all stakeholders.” Full
Value-Based Contracts Provide Promise and Potential
(1/9, Dan Leonard, Chain Drug Review) comments “...[T]here is uncertainty about how the anti-kickback statute aligns with value-based contracting. In NPC's view, the statute prohibits biopharmaceutical manufacturers from using risk management tools that could improve patient outcomes. Research shows that 20% to 30% of prescriptions are never filled, and as many as 50% are not taken as prescribed. Estimates suggest this nonadherence costs our health care system between $100 billion and $289 billion every year. If more safe harbors are created, manufacturers could institute programs that give patients the best chance of successful treatment, bolstered by education, coaching, case management and monitoring.” Full
New Drug Entry Versus Existing Product Inflation: What's Driving Rising US Drug Costs?
(1/8, Jaime Rosenberg, The American Journal of Managed Care) reports “...Despite few new blockbuster drugs entering the market, the average costs of oral and injectable brand-name drugs increased an average of 9.2% and 15.1%, respectively, each year of the study period...According to the authors, these estimates demonstrate the role of existing product price inflation on rising drug costs. ‘This is particularly important because in the current value-based landscape, increasing drug costs attributable to new products can sometimes be justified on the basis of improved outcomes,’ they wrote. ‘However, rising costs due to inflation do not reflect improved value for patients.’” Full
Value-Based Agreements Take Center Stage at COA Summit
(1/9, Surabhi Dangi-Garimella, PhD, Targeted Oncology) reports “...‘Congress continues to ask us the same questions [about the cost of healthcare], and we continue looking for different answers. Value-based agreements are the current innovative solution’ to improving quality and reducing healthcare costs, said [Jeff Mortier, partner at Farragut Partners]. ‘Adequate treatment and adherence in chronic conditions can save $213 billion,’ he explained.” Full
Using Precision Medicine to Treat the Long Arc of Disease
(1/9, Laura Joszt, The American Journal of Managed Care) reports “...While precision medicine applies to almost every disease, it got started with cancer, which is unique to each person. Adaptive is now partnering with Genentech to design a truly personalized therapy to look at a specific person's cancer and the immune response to the tumor. [Chad Robins, chief executive officer and cofounder of Adaptive Biotechnologies Corporation] provided the analogy of purchasing a suit. Before personalized medicine, it was like buying a suit with no sizing. Now, with different biomarkers, it's like finding the right size on the rack. With personalized medicine, a suit can be custom designed and tailored for each individual person.” Full
How Are ACOs Using Segmentation to Manage High-Need, High-Cost Patients?
(1/8, Allison Inserro, The American Journal of Managed Care) reports “...Many ACOs have used predictive modeling and risk stratification to sort their entire population into broad risk levels. But with 5% of patients in the United States accounting for 50% of healthcare spending, even further division of patients into smaller subgroups has been suggested as a way to create targeted interventions and use limited resources, the report noted.” Full
UK: Stivarga Final NICE Recommendation for Hepatocellular Carcinoma
(1/9, Anna Smith, PharmaTimes) reports “Bayer's Stivarga has received a final green light from the National Institute for Health and Care Excellence for use by the NHS to treat advanced liver cancer. Stivarga (regorafenib) is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had Nexavar (sorafenib), but only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group performance status of 0 or 1.” Full
The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs
Inmaculada Hernandez, et al.
January 2019, Health Affairs
The Frequency and Availability of Population-Specific Patient Reported Outcome Measures and Minimal Clinically Important Differences among Approved Drugs in Canada
Soprovich A, Ingstrup M, Eurich DT.
January 7, 2019, Health and Quality of Life Outcomes
How Accountable Care Organizations Use Population Segmentation to Care for High-Need, High-Cost Patients
January 3, 2019
The Commonwealth Fund
HEOR & RWE: Global Sourcing Strategies and Best Practices
January 24, 2019